Washington Court Mandates Coverage for Weight-Loss Medications

The Washington Court of Appeals has mandated that health insurers in Washington state must not categorically exclude coverage for weight-loss medications, including GLP-1 drugs such as Ozempic, Wegovy, and Manjaro. Previously, insurers often denied these treatments citing them as costly and ineffective. However, GLP-1 medications improve insulin regulation and suppress appetite, redefining their role in weight management.

In 2005, GLP-1 drugs were approved mainly for diabetes management, but their scope has expanded. The court now requires insurers to justify excluding weight-loss prescriptions, aligning this with Washington's legal stance that recognizes obesity as a disability. This follows a pivotal 2019 Supreme Court ruling protecting individuals from weight discrimination.

The lawsuit involved nurse Jeannette Simonton, who faced insurer refusal for obesity medication necessary for knee surgery preparation. Despite personal expenses, Simonton achieved weight loss with GLP-1 treatment. Judge Ian Birk ruled that coverage exclusions based on disabilities require substantial justification and not mere precedent.

Professor Joey Mattingly from the University of Utah predicts policy changes as evidence grows and costs adjust, potentially leading more employers to cover these medications. The ruling's implications extend beyond weight-loss drugs to other recognized disabilities, potentially affecting coverage for mental health care and hearing aids, as noted by Emily Brice from Northwest Health Law Advocates. Insurance professionals should monitor these developments, as they could influence coverage policies and premium structures.